Preclinical Acquisitional Due Diligence rises as a major focus of CPSRC

Rounding out the first business quarter, Dr. Hampshire reports that a majority of questions and problems large companies face is related to due diligence in examination and interpretation of preclinical data.  Common regulatory problems include lack of reporting full diagnostic information on adverse events in preclinical trials, a need for better animal health records, and a better focus on gross necropsy records and reports.